Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation

Abstract

More than 700 pathogenic or probably pathogenic variations have been identified in the RYR1 gene causing various myopathies collectively known as “ RYR1 -related myopathies”. Currently, there is no treatment for these myopathies, and gene therapy stands out as one of the most promising approaches. In the context of a dominant form of Central Core Disease due to a RYR1 mutation, we aimed at showing the functional benefit of inactivating specifically the mutated RYR1 allele by guiding CRISPR/Cas9 cleavages onto frequent single nucleotide polymorphisms (SNPs) segregating on the same chromosome. Whole-genome sequencing was used to pinpoint SNPs localized on the mutant RYR1 allele and identified specific CRISPR/Cas9 guide-RNAs. Lentiviruses encoding these guide-RNAs and the SpCas9 nuclease were used to transduce immortalized patient muscle cells, inducing the specific deletion of the mutant RYR1 allele. The efficiency of the deletion was assessed at both DNA and RNA levels and at the functional level after monitoring calcium release induced by the stimulation of the RyR1-channel. This study provides in-cellulo proof of concept regarding the benefits of mutant RYR1 allele deletion, in the case of a dominant RYR1 mutation, from both a molecular and functional perspective. Graphical abstract eTOC synopsis Mutations in the RYR1 gene, encoding a calcium channel required for muscle contraction, cause severe myopathies. In this study, Marty and colleagues demonstrate the functional benefit of suppression of a mutant RYR1 allele using CRISPR/Cas9, in the case of a dominant mutation, leaving the wild type allele alone.

Functional and molecular profiles of the neuroretina and retinal pigmented epithelium-choroid in response to aging and Nrf2 deletion
B. L. Wells, A. J. Filiberti, D. R. Stanford +5
bioRxiv8 Oct 2026PreprintAll rights reservedFull textMolecular biology & gene regulationbioRxiv
Variable alterations in frequencies of CRISPR/Cas9-induced nucleotide deletion and insertion in transgenic maize callus tissues exposed to chromatin modifiers.
Bettina Nagy, Aysha Jameel, Gábor V Horváth +8
Frontiers in genome editing7 Oct 2026Peer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
Towards Accurate Prediction of Mutation-Induced Changes in Protein Structure
Zhuoyi Liu, Alex Calabrese, Corey S. O'Hern
arXiv21 Sep 2026PreprintarXiv licenceFull textBiophysics Biological & medical physicsarXiv
Protection against diet-induced weight gain by a single-point mutation in Kir2.1 channels
Katie M. Beverley, Marcos D. Munoz, Sang Joon Ahn +6
Scientific Reports6 Aug 2026Peer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
Computational Investigation of S781F Mutation-Induced Remodeling of the Staphylococcal Nuclease Domain-Containing Protein 1–Argonaute 2 Interface
Jittasak Khowsathit, Yuvaraj Ravikumar, Manu Deeudom +4
International Journal of Molecular Sciences30 Sep 2026Peer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC

Cite

BibTeX RIS

BibTeX

@article{beaufils2026functional,
  title = {{Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation}},
  author = {Mathilde Beaufils and Margaux Melka and Julie Brocard and Clement Benoit and Nagi Debbah and Kamel Mamchaoui and Norma Romero and Anne Frédérique Dalmas-Laurent and Susana Quijano-Roy and Julien Fauré and John Rendu and Isabelle Marty},
  journal = {Molecular Therapy - Nucleic Acids},
  year = {2026},
  month = oct,
  doi = {10.1016/j.omtn.2024.102259},
  url = {https://hal.science/hal-05788866v1},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation
AU  - Mathilde Beaufils
AU  - Margaux Melka
AU  - Julie Brocard
AU  - Clement Benoit
AU  - Nagi Debbah
AU  - Kamel Mamchaoui
AU  - Norma Romero
AU  - Anne Frédérique Dalmas-Laurent
AU  - Susana Quijano-Roy
AU  - Julien Fauré
AU  - John Rendu
AU  - Isabelle Marty
PY  - 2026
DA  - 2026/10/09
JO  - Molecular Therapy - Nucleic Acids
DO  - 10.1016/j.omtn.2024.102259
UR  - https://hal.science/hal-05788866v1
AB  - More than 700 pathogenic or probably pathogenic variations have been identified in the RYR1 gene causing various myopathies collectively known as “ RYR1 -related myopathies”. Currently, there is no treatment for these myopathies, and gene therapy stands out as one of the most promising approaches. In the context of a dominant form of Central Core Disease due to a RYR1 mutation, we aimed at showing the functional benefit of inactivating specifically the mutated RYR1 allele by guiding CRISPR/Cas9 cleavages onto frequent single nucleotide polymorphisms (SNPs) segregating on the same chromosome. Whole-genome sequencing was used to pinpoint SNPs localized on the mutant RYR1 allele and identified specific CRISPR/Cas9 guide-RNAs. Lentiviruses encoding these guide-RNAs and the SpCas9 nuclease were used to transduce immortalized patient muscle cells, inducing the specific deletion of the mutant RYR1 allele. The efficiency of the deletion was assessed at both DNA and RNA levels and at the functional level after monitoring calcium release induced by the stimulation of the RyR1-channel. This study provides in-cellulo proof of concept regarding the benefits of mutant RYR1 allele deletion, in the case of a dominant RYR1 mutation, from both a molecular and functional perspective. Graphical abstract eTOC synopsis Mutations in the RYR1 gene, encoding a calcium channel required for muscle contraction, cause severe myopathies. In this study, Marty and colleagues demonstrate the functional benefit of suppression of a mutant RYR1 allele using CRISPR/Cas9, in the case of a dominant mutation, leaving the wild type allele alone.
SN  - 2162-2531
ER  -

Abstract

Related

Cite